| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.8 | 0.0 |
| Profit before tax | -5.9 | -7.0 |
| Net income | -5.9 | -7.0 |
| EPS (diluted, $ a share) | $-0.01 | $-0.01 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: MREO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Mereo BioPharma Group plc: key numbers
- Share price
- $0.2745Close, Nov 17
- Market cap
- $219M
- Shares outstanding
- 798.5MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Mereo BioPharma Group plc
All →Mereo BioPharma Group Financial Results
Mereo BioPharma reported third quarter 2026 financial results and provided updates on its rare disease pipeline, including setrusumab for osteogenesis imperfecta and alvelestat for AATD-LD. The company ended the quarter with $26.1 million in cash, which is expected to fund operations into late-2027, excluding potential milestone payments from partners Ultragenyx and Sentynl Therapeutics.
“During the third quarter, we have made meaningful progress on our two core programs, setrusumab and alvelestat. These developments have the potential to set the stage for a transformational 2027 for Mereo, our shareholders and the patients we aim to serve.”
Denise Scots-Knight, Chief Executive Officer of Mereo BioPharma